Request for Quote.pdf

REQUEST FOR QUOTE (RFQ)

(1) Action Type: Combined Synopsis / Solicitation

(2) Date: July 20, 2022

(3) Title: Synthesis of Specialty Compounds

(4) Solicitation Number: 75N92022Q0404

(5) Classification Code: Q301, Medical Laboratory Testing

(6) Contracting Office Address:

6705 Rockledge Drive RKL1, Office of Acquisitions Bethesda, MD 20892

(7) Closing Response Date: August 4, 2022

(8) Contact Point: Nicole Freid, Contract Specialist; nicole.freid@nih.gov; 301-827-2818

(9) Contract Line Item(s):

a. Line Item 1: Target 5, 10-20mg

b. Line item 2: Target 6, 10-20mg

c. Line item 3: Target 7, 10-20mg

d. Line item 4: Target 8, 10-20mg

e. Line Item 5: Target 12, 10-20mg

f. Line item 6: Target 4, 10-20mg

g. Line item 7: Target 13, 10-20mg

h. Line item 8: Target 14, 10-20mg

i. Line Item 9: -Target 15, 10-20mg

j. Line item 10: -Target 16, 10-20mg

k. Line item 11: -Target 11, 10-20mg

(10) Description:

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N92022Q0404 and the solicitation is issued as a request for quote (RFQ).

(iii) The solicitation document and the incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2022-06 effective May 26, 2022.

(iv) The associated NAICS code is 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology, and the small business size standard is 1,000 Employees. This acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13.

This Solicitation has been set aside for Total Small Business Set Aside in accordance with FAR 19.5.

(v) Contractor Requirements:

NHLBI requires a contract to procure Synthesis of 11 Compounds for research supporting the Project: Development of proteolysis targeting chimera’s (PROTACs) for dual leucine zipper kinase (DLK).

*STRUCTURES ARE ONLY AVAILABLE TO BIDDERS WHO ARE WILLING TO SIGN

THE CONFIDENTIAL DISCLOSURE AGREEMENT (CDA) FORM*.

Please reach out to contract specialist Nicole Freid at nicole.freid@nih.gov for the form and additional information.

See attached Statement of Need for additional information.

(vi) Estimated Delivery:

The expected delivery date is 12-14 weeks after receipt of order, and shall work with the end user.

Anticipated delivery time needs to be included in the quote.

Require Inside Delivery To:

NIH/NHLBI/CSC

9800 Medical Center Dr Building B, Room 2033A Rockville, MD 20850

Contract Clauses: The following contract clauses apply:

The provision at FAR clause 52.212-2, Evaluation – Commercial Items, is applicable.

An award will be made on a competitive basis using a comparative evaluation of all quotes received.

Evaluation will be done to identify all offerors whose quotes demonstrate the ability to provide the services listed in section 10 above. The specific evaluation factor is Lowest Price Technically Acceptance (LPTA), and is attached.

FAR clause 52.212-3, Offeror Representations and Certifications – Commercial Items, is applicable. An offeror shall complete only paragraphs (b) of this provision if the offeror has completed the annual representations and certificates electronically via http://www.acquisition.gov. If an offeror has not completed the annual representations and certifications electronically at the System for Award Management (SAM) website, the offeror shall complete only paragraphs (c) through (p) of this provision.

FAR clause at 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition.

FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders – Commercial Items, applies to this acquisition. Including the following clauses and Prohibitions:

(a) The Contractor shall comply with the following Federal Acquisition Regulation (FAR) clauses, which are incorporated in this contract by reference, to implement provisions of law or Executive orders applicable to acquisitions of commercial items:

(1) 52.203-19, Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements (Jan 2017) (section 743 of Division E, Title VII, of the Consolidated and Further Continuing Appropriations Act, 2015 (Pub. L. 113-235) and its successor provisions in subsequent appropriations acts (and as extended in continuing resolutions)).

(2) 52.204-23, Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (NOV 2021) (Section 1634 of Pub. L. 115-91).

(3) 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment. (NOV 2021) (Section 889(a)(1)(A) of Pub. L. 115-232).

(4) 52.209-10, Prohibition on Contracting with Inverted Domestic Corporations (Nov 2015).

(5) 52.233-3, Protest After Award (Aug 1996) (31 U.S.C. 3553).

(6) 52.233-4, Applicable Law for Breach of Contract Claim (Oct 2004) (Public Laws 108-77 and 108-78 (19 U.S.C. 3805 note)).

(b) The Contractor shall comply with the FAR clauses in this paragraph (b) that the Contracting Officer has indicated as being incorporated in this contract by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items:

i. 52.219-6 Notice of Total Small Business Set Aside

ii. 52.219-28 Post Award Small Business Program Rerepresentation

iii. 52.222-3, Convict Labor

iv. 52.222-19 Child Labor-Cooperation with Authorities and Remedies

v. 52.222-21, Prohibition of Segregated Facilities

vi. 52.222-26, Equal Opportunity

vii. 52.222-36, Equal Opportunity for Workers with Disabilities

viii. 52.222-50 Combating Trafficking in Persons

ix. 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving

x. 52.225-13, Restrictions on Certain Foreign Purchases

xi. 52.225-25, Prohibition on Contracting with Entities Engaging in Certain Activities or Transactions Relating to Iran-Representation and Certifications

xii. 52.232-33, Payment by Electronic Funds Transfer—System for Award Management

(xi) Quotes shall be submitted via email to Nicole Freid, Contracting Specialist at nicole.freid@nih.gov and through the FedConnect web portal (www.fedconnect.net). The due date for receipt of quotes is 05:00PM EST on August 4, 2022. Late quotes will not be accepted.

https://www.acquisition.gov/far/52.225-25#FAR_52_225_25 mailto:nicole.freid@nih.gov

Vendors can register with FedConnect at the following address:

https://www.fedconnect.net/FedConnect/default.htm.

Please note that FedConnect is used by multiple federal agencies and therefore FedConnect assistance will be provided by Compusearch Software Systems, not the NHLBI OA. More information about registration requirements can be found by downloading the FedConnect Ready, Set, Go! Guide at the following address:

https://www.fedconnect.net/fedconnect/Marketing/Documents/FedConnect_Ready_Set_Go.pdf.

For assistance in registering or for other technical questions please call the FedConnect Help Desk at 800-899-6665 or email at support@fedconnect.net

STATEMENT OF NEED

Project Title

Order of the Synthesis of 11 Compounds for Research Supporting The Project: Development of proteolysis targeting chimera’s (PROTACs) for dual leucine zipper kinase (DLK). PI: John Brognard

Background Information/Purpose and Objectives

From time to time the Chemistry and Synthesis Center (CSC) enlists the help of outside vendors for the synthesis of specialty compounds in an effort to save research cost and resources. These specialty compounds often require complicated synthesis pathways which very few vendors can perform. Over the years the CSC has found certain vendors who have proven reliable in terms of capability, quality, cost and lead time.

Carolyn Hitko, a CSC chemist, is currently conducting research in support of the project: Development of proteolysis targeting chimera’s (PROTACs) for dual leucine zipper kinase (DLK), PI: John Brognard. This project includes sixteen compounds to be synthesized. To save time and resources, the CSC needs the help of an outside vendor to synthesize 11 of these compounds.

Product Specifications

Below is the list of the 11 compounds needing outside vendor synthesis:

Target #4,5,6,7,8,11,12,13,14,15,16 (Structures are available to bidders who are willing to sign a

CDA)

We require inside delivery to:

NIH/NHLBI/CSC

9800 Medical Center Dr Building B, Room 2033A Rockville, MD 20850

POC for Delivery:

Melanie Fensick 301-827-8022 melanie.fensick@nih.gov

EVALUATION CRITERIA

Topic Notes Synthesis of Specialty Compounds Ability to deliver the contractor’s requirements stated in the Request For Quote (RFQ) at the Lowest Price Technically Acceptable (LPTA).